Scientist I, Biophysics, Mechanism of Action
Revolution Medicines
Summary
As a key member of our dynamic Mechanism of Action team within Discovery Biology under the Biomedical Discovery Research (BDR) department, you will have responsibilities including, but not limited to:
Job description
The Opportunity
As a key member of our dynamic Mechanism of Action team within Discovery Biology under the Biomedical Discovery Research (BDR) department, you will have responsibilities including, but not limited to:
- Design, develop, and perform label-free biophysical assays (BLI, SPR) to inform the mode of action of small molecule, tri-complex inhibitors, and protein-effector interactions
- Develop/troubleshoot bespoke SPR methods to understand the mechanism of tri-complex inhibition
- Design and perform SPR assays to support regulatory documentation
- Transfer established methods for routine screening
- Perform data analysis, prepare experimental result reports, upload data to electronic notebooks, author IND/NDA reports, and present findings to project teams
Required Skills, Experience and Education
- PhD in biological sciences or a related scientific discipline, with 0-2 years of industry experience
- In-depth experience in operating, troubleshooting, and maintaining SPR (Cytiva Biacore or Carterra LSA) and BLI (Octet or Gator) systems
- Extensive experience in SPR method development and data analysis, including working knowledge of different sensor surface chemistry, novel injection methods (eg dual inject, ABA), and analysis methods
- Experience in working with diverse sample types (cell lysates, purified proteins, clarified supernatant)
- Ability to manage multiple laboratory and project tasks efficiently
- Ability to work effectively in a flexible, team-oriented environment
- Highly organized and detail-oriented, with excellent recordkeeping skills and the ability to adapt to a dynamic, fast-paced environment
Preferred Skills
- Experience performing label-free biophysical assays with biologics and covalent inhibitors
- Prior experience with epitope binning, titer determination, off-rate ranking
- Previous hands-on experience with TR-FRET assay development
- Prior experience with biophysical techniques such as DLS, DSF, and SEC
- Prior experience with automated liquid handling systems (Opentrons, Hamiliton STAR, DragonFly, Tecan systems)
Requirements
- PhD in biological sciences or a related scientific discipline
- 0-2 years of industry experience
- In-depth experience operating, troubleshooting, and maintaining SPR (Cytiva Biacore or Carterra LSA) and BLI (Octet or Gator) systems
- Extensive experience in SPR method development and data analysis
- Working knowledge of sensor surface chemistry, novel injection methods (dual inject, ABA), and analysis methods
- Experience working with diverse sample types (cell lysates, purified proteins, clarified supernatant)
- Ability to manage multiple laboratory and project tasks efficiently
- Ability to work effectively in a flexible, team-oriented environment
- Highly organized and detail-oriented with excellent recordkeeping skills
Benefits
- Competitive Cash Compensation
- Equity Awards
- Health Benefits
- Learning & Development
Company overview
Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies for RAS-addicted cancers. The company is pioneering a new class of therapeutics that target oncogenic RAS mutations, which are among the most common drivers of human cancers. Revolution Medicines employs a unique approach to drug discovery, leveraging deep insights into RAS biology to develop small molecule inhibitors that can address previously undruggable targets. Their pipeline includes multiple clinical-stage candidates designed to inhibit various RAS pathway mutations, with a particular focus on KRAS G12C and other RAS variants. The company's scientific platform combines structural biology, medicinal chemistry, and computational approaches to design highly selective inhibitors. Revolution Medicines aims to transform cancer treatment by developing therapies that can overcome resistance mechanisms and provide durable clinical benefits for patients with RAS-driven malignancies. Their research represents a significant advancement in the field of targeted cancer therapy, addressing one of the most challenging areas in oncology drug development.